Your browser doesn't support javascript.
loading
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.
Robles, Eloy F; Mena-Varas, Maria; Barrio, Laura; Merino-Cortes, Sara V; Balogh, Péter; Du, Ming-Qing; Akasaka, Takashi; Parker, Anton; Roa, Sergio; Panizo, Carlos; Martin-Guerrero, Idoia; Siebert, Reiner; Segura, Victor; Agirre, Xabier; Macri-Pellizeri, Laura; Aldaz, Beatriz; Vilas-Zornoza, Amaia; Zhang, Shaowei; Moody, Sarah; Calasanz, Maria Jose; Tousseyn, Thomas; Broccardo, Cyril; Brousset, Pierre; Campos-Sanchez, Elena; Cobaleda, Cesar; Sanchez-Garcia, Isidro; Fernandez-Luna, Jose Luis; Garcia-Muñoz, Ricardo; Pena, Esther; Bellosillo, Beatriz; Salar, Antonio; Baptista, Maria Joao; Hernandez-Rivas, Jesús Maria; Gonzalez, Marcos; Terol, Maria Jose; Climent, Joan; Ferrandez, Antonio; Sagaert, Xavier; Melnick, Ari M; Prosper, Felipe; Oscier, David G; Carrasco, Yolanda R; Dyer, Martin J S; Martinez-Climent, Jose A.
Afiliación
  • Robles EF; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Mena-Varas M; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Barrio L; Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid 28049, Spain.
  • Merino-Cortes SV; Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid 28049, Spain.
  • Balogh P; Department of Immunology and Biotechnology, Szentágothai Research Center, University of Pécs, Pécs H-7624, Hungary.
  • Du MQ; Division of Molecular Histopathology, Department of Pathology, Cambridge University, Cambridge CB2 1QP, UK.
  • Akasaka T; MRC Toxicology Unit and Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK.
  • Parker A; Department of Haematology, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK.
  • Roa S; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Panizo C; Department of Hematology, Clinica Universidad de Navarra, IDISNA, Pamplona 31008, Spain.
  • Martin-Guerrero I; Institute of Human Genetics, Christian-Albrechts-University Kiel &University Hospital Schleswig-Holstein, Campus Kiel, Kiel 24105, Germany.
  • Siebert R; Institute of Human Genetics, Christian-Albrechts-University Kiel &University Hospital Schleswig-Holstein, Campus Kiel, Kiel 24105, Germany.
  • Segura V; Bio-informatic Unit, Department of Genomics and Proteomics, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Agirre X; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Macri-Pellizeri L; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Aldaz B; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Vilas-Zornoza A; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Zhang S; Division of Molecular Histopathology, Department of Pathology, Cambridge University, Cambridge CB2 1QP, UK.
  • Moody S; Division of Molecular Histopathology, Department of Pathology, Cambridge University, Cambridge CB2 1QP, UK.
  • Calasanz MJ; Department of Genetics, School of Medicine, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Tousseyn T; Centre for Translation Cell and Tissue Research, KU Leuven, Leuven 3000, Belgium.
  • Broccardo C; Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, Labex TOUCAN and CRCT INSERM U1037, Toulouse F-31053, France.
  • Brousset P; Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, Labex TOUCAN and CRCT INSERM U1037, Toulouse F-31053, France.
  • Campos-Sanchez E; Centro de Biologia Molecular Severo Ochoa, CSIC/Universidad Autonoma, Madrid 28049, Spain.
  • Cobaleda C; Centro de Biologia Molecular Severo Ochoa, CSIC/Universidad Autonoma, Madrid 28049, Spain.
  • Sanchez-Garcia I; Experimental Therapeutics and Translational Oncology Program, Institute of Molecular and Cellular Biology of Cancer, CSIC/University of Salamanca; and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.
  • Fernandez-Luna JL; Molecular Genetics Unit, University Hospital Marques de Valdecilla and IFIMAV, Santander 39011, Spain.
  • Garcia-Muñoz R; Hematology Department, Hospital San Pedro, Logroño, 26006, La Rioja, Spain.
  • Pena E; Department of Hematology, Complejo Hospitalario de Navarra, Servicio Navarro de Salud, IDISNA, Pamplona 31008, Spain.
  • Bellosillo B; Department of Pathology, Cancer Research Program, Institut Municipal d'Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona 08003, Spain.
  • Salar A; Department of Clinical Hematology, Cancer Research Program, Institut Municipal d'Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona 08003, Spain.
  • Baptista MJ; Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona 08916, Spain.
  • Hernandez-Rivas JM; Department of Hematology, IBSAL-University Hospital and IBMCC-CSIC, University of Salamanca, Salamanca 37007, Spain.
  • Gonzalez M; Department of Hematology, IBSAL-University Hospital and IBMCC-CSIC, University of Salamanca, Salamanca 37007, Spain.
  • Terol MJ; Department of Hematology, Hospital Clinico, INCLIVA Biomedical Research Institute, University of Valencia, Valencia 46010, Spain.
  • Climent J; Department of Hematology, Hospital Clinico, INCLIVA Biomedical Research Institute, University of Valencia, Valencia 46010, Spain.
  • Ferrandez A; Department of Pathology, Hospital Clinico, University of Valencia, Valencia 46010, Spain.
  • Sagaert X; Centre for Translation Cell and Tissue Research, KU Leuven, Leuven 3000, Belgium.
  • Melnick AM; Department of Medicine/Hematology-Oncology, Weill Cornell Medical College, New York, New York 10065, USA.
  • Prosper F; Division of Hemato-Oncology, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona 31008, Spain.
  • Oscier DG; Department of Hematology, Clinica Universidad de Navarra, IDISNA, Pamplona 31008, Spain.
  • Carrasco YR; Department of Haematology, Royal Bournemouth Hospital, Bournemouth BH7 7DW, UK.
  • Dyer MJ; Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid 28049, Spain.
  • Martinez-Climent JA; MRC Toxicology Unit and Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK.
Nat Commun ; 7: 11889, 2016 06 14.
Article en En | MEDLINE | ID: mdl-27297662
ABSTRACT
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Factores de Transcripción / Linfocitos / Receptores de Antígenos de Linfocitos B / Transducción de Señal / Linfoma de Células B de la Zona Marginal / Proteínas de Homeodominio Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2016 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Factores de Transcripción / Linfocitos / Receptores de Antígenos de Linfocitos B / Transducción de Señal / Linfoma de Células B de la Zona Marginal / Proteínas de Homeodominio Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2016 Tipo del documento: Article País de afiliación: España